Dr. Monk graduated at the top of his class from the University of Arizona College of Medicine in 1988, and completed a residency in obstetrics and gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in medical genetics and gynecologic oncology. In 1995, Dr Monk was appointed director of gynecologic oncology at Texas Tech University Health Services Center and, from 1998 until recently, was associate professor of obstetrics and gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr Monk is currently professor in the Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix.
Dr. Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He is an investigator for the Gynecologic Oncology Group (GOG) and is the Group’s Cervical and Vulvar Committee Chair and also a member of the Tissue Utilization, Publications, and Protocol Development committees.
Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncologists, the American Society of Clinical Oncology and the American Association for Cancer Research and other professional organizations. He is a current member of the editorial boards of several journals, including Gynecologic Oncology and Clinical Ovarian Cancer, and a reviewer for journals including Clinical Cancer Research, Obstetrics and Gynecology, Cancer and Journal of Clinical Oncology.
Dr. Monk has authored more than 150 peer-reviewed articles dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.